AZD1222 (Oxford-AstraZeneca)
phone-call sandwich
AZD1222 (Oxford-AstraZeneca)

AZD1222 (Oxford-AstraZeneca)

The AZD1222 comes from the ChAdOx1 adenovirus that infects chimpanzees. It was developed by the Anglo-Swedish company AstraZeneca.
AstraZeneca

AstraZeneca

In the fall, studies of AZD1222 were interrupted after a case of transverse myelitis was detected in one subject, but were then resumed. Though Phase III trials are not yet complete, the vaccine has already been approved for use in the United Kingdom, India and several other countries. In December 2020, AstraZeneca announced its collaboration with the Gamaleya Center, which developed the Sputnik-V vaccine. It is presumed that a combination of the two vaccines will boast even higher effectiveness.

Vaccine

AZD1222 (Oxford-AstraZeneca)

Developer

AstraZeneca

Producer

  • AstraZeneca manufactures the vaccine at SK BioScience (South Korea)

  • Wockhardt UK (United Kingdom)

Status

The vaccine is currently in Phase III clinical trials.

Key information

What’s in the vaccine?

A vector vaccine is the part responsible for delivering biomaterial into cells of the human body cells. AstraZeneca’s vaccine is based on an adenovirus that commonly attacks chimpanzees.
ChAdOx1 is not dangerous to humans, as the immune system does not react to it.

Vaccines developed and used in Russia